Sale!

TUKAVO 150MG

Name: TUKAVO 150MG
Brand: Zydus Lifesciences Limited
SKU: 494
Availability: InStock

TUCATINIB TABLETS 150MG

containing 60 tablets

TUKAVO 150MG is a formulation of tucatinib, a targeted therapy used in the treatment of HER2-positive breast cancer.

Tucatinib: A tyrosine kinase inhibitor that selectively targets the HER2 receptor, which is overexpressed in certain breast cancers.

Inhibits HER2 signaling: Tucatinib blocks intracellular HER2 activity, reducing cancer cell proliferation.
Improves progression-free survival: When used with trastuzumab and capecitabine, it significantly delays disease progression in HER2-positive breast cancer patients.
Effective in brain metastases: Tucatinib has shown activity against HER2-positive tumors that have spread to the brain, a major challenge in advanced breast cancer.
Well-tolerated: Compared to other HER2-targeted therapies, tucatinib has a favorable safety profile, with manageable side effects like diarrhea and elevated liver enzymes.

Interacting Agent	Effect	Recommendation
Strong CYP3A inhibitors (e.g. ketoconazole, clarithromycin)	↑ Tucatinib levels → ↑ toxicity risk	Avoid or monitor closely
Strong CYP3A inducers (e.g. rifampin, carbamazepine)	↓ Tucatinib levels → ↓ effectiveness	Avoid combination
P-gp inhibitors (e.g. amiodarone, verapamil)	↑ Tucatinib exposure	Monitor for side effects
Capecitabine (used in combo therapy)	No direct interaction, but additive GI toxicity	Monitor for diarrhea, nausea
Trastuzumab (used in combo therapy)	No known interaction	Safe when used as directed

Strength: 150 mg per tablet
Route: Oral
Frequency: Usually taken twice daily, but exact dosing depends on the treatment regimen
With or without food: Can be taken either way, but consistency is key

TUKAVO 150MG, containing tucatinib, is a targeted oral therapy used for HER2-positive metastatic breast cancer.

Take consistently: With or without food, but stick to the same routine daily
Swallow whole: Do not crush or chew the tablet
Combination therapy: Usually prescribed with trastuzumab and capecitabine
Hydration: Maintain adequate fluid intake, especially if experiencing diarrhea
Monitoring: Regular liver function tests and symptom tracking are essential

Company